UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 29, 2024
(Exact name of registrant as specified in charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||||||||||||
| of incorporation) | File Number) | Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (770 ) 651-9100
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 29, 2024, the Board of Directors (the “Board”) of MiMedx Group, Inc. (the “Company”), approved an increase in the size of the Board to eleven members and appointed two new members, Ms. Tiffany P. Olson and Ms. Dorothy E. Puhy, to the Board, effective March 1, 2024.
The Company issued a press release in connection with the appointments, which is included as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description of Exhibit | ||||
| 99.1 | |||||
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MIMEDX GROUP, INC. | ||||||||
| March 4, 2024 | By: | /s/William F. Hulse IV | ||||||
| William F. Hulse IV General Counsel and Chief Administrative Officer | ||||||||
MIMEDX Announces Appointment of Two New Independent Directors
MARIETTA, Ga., March 4, 2024 -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously agreed to expand its size to eleven directors.
M. Kathleen Behrens, Chair of the Board at MIMEDX, stated, “On behalf of the entire Board of Directors, we are honored to welcome these accomplished business leaders who will undoubtedly contribute to our strategic vision and provide unique and valuable insights. We look forward to working together to unlock the full potential MIMEDX has to offer the industry as a leader in innovative Wound Care and Surgical therapeutics.”
Joseph H. Capper, MIMEDX Chief Executive Officer, added, “Tiffany and Dorothy will be exceptional additions to the Board. These individuals have highly complementary skill sets, which, coupled with their proven track records of leadership and influence at prominent organizations across healthcare and other industries, will elevate our Board as a whole.”
About Tiffany Olson
Ms. Olson currently serves as a board member for two other public companies, Telix Pharmaceuticals and Castle Biosciences, and a privately held growth-stage company, Langham Logistics. She previously held CEO, president, and senior leadership positions in the U.S. and Europe at multiple international Fortune 100 healthcare companies, including Cardinal Health, Roche, and Eli Lilly.
About Dorothy Puhy
Ms. Puhy has previously held board positions at Abiomed, Azenta, Eaton Vance, Reebok, and other privately held companies. She has also held several executive leadership positions, including CFO and EVP, COO of Dana-Farber Cancer Institute and EVP, CFO of New England Medical Center (now Tufts Medical Center).
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com